Anavex Life Sciences Corp (AVXL)

[nidan7500]

Poster text:

Randomized,placebo-controlledclinicaltrialin132patientswith Parkinson’sdiseasedementia(PDD)includedprespecifiedbiomarkersof responseaswellasWholeExomeSequencingDNAdataandfullRNA exomeexpressiondatacollection.Thisstudydemonstrateddosedependent,statisticallysignificantimprovementofdementiaassessment, QualityofEpisodicMemorywithANAVEX®2-73(p=0.003)aswellas significantimprovementofParkinson’sassessment,MDS-UPDRSTotal score(p=0.034)forpatientstreatedwithANAVEX®2-73highoraldose oncedailyduring14-weektrial •ANAVEX®2-73transcriptomicsanalysis(RNAseq),identifiedagene networkthatisdifferentiallyexpressedinParkinson’sdiseasedementia (PDD)patientstreatedwithANAVEX®2-73comparedtoplaceboafter14 weeksoftreatment •Biologicalrelevanceofthisgenenetworkwasassessedthroughpathway analysisandconfirmedtheimpactofANAVEX®2-73treatmenton pathwaysinvolvedinneurodegenerativediseases,especiallyAlzheimer’s diseaseandParkinson’sdisease •Whilegenesaredown-regulatedinAlzheimer’sdiseaseand Parkinson’sdisease,ANAVEX®2-73singularlyimpactedexpression levelsofthesegenesinmultiplepathwaysbycounteringthe pathologicaldown-regulationofgenesinbothAlzheimer’s(p<0.005) andParkinson’sdisease(p<0.005)andotherdegenerativediseases (p<0.005)andthesemayrepresentadditionalpotentialbiomarkersof diseasepathologyandresponse

Unambiguous , IMO cautious...understated considering what is at stake.